This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

5 ETFs for Value-Based Pharma Believers

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK (ETF Expert) -- Abbott Laboratories (ABT) sports five-year dividend growth of nearly 10% as well as a 3.5%+ annualized yield. Eli Lilly (LLY) has a P/E of 9, a 5.3% dividend yield and three-year earnings growth of 19%. Meanwhile, AstraZeneca (AZN) has a mammoth 35% trailing return on equity with a 5.8% annual dividend payout.

How in the world are investors overlooking the pharma space? Actually, the smart money hasn't overlooked it. The iShares DJ Pharmaceuticals Fund (IHE) is part of a select group of stock ETFs with a price above a 200-day moving average. In fact, not many stock ETFs in that select group can lay claim to year-to-date gains of about 8%.

There are four pharmaceutical ETFs for those intrigued by a value-driven uptrend. Each tends to capitalize on slightly different aspects of the drug universe. For example, SPDR S&P Pharma (XPH) maintains an equal weight strategy across 30 companies, which may lead to a greater focus on growth from the "anti Johnson & Johnsons." It follows that the yield is less compelling, but the potential for capital appreciation may be much greater.

The aforementioned IHE is relatively similar to XPH; both are less yield-oriented than pharma stocks are known for. That said, IHE is 1/4 less volatile than the S&P 500 whereas XPH is only a "skosh" less volatile than the U.S. benchmark.

In complete contrast, the Pharmaceutical HOLDRS (PPH) is dominated by Johnson & Jonhson (JNJ) with a 25% allocation. With only a handful of the largest brand name constituents moving PPH's needle -- Merck, Eli Lilly, Pfizer, etc. -- the yield is more compelling (approx 3%), but the growth prospects are less so.

The PowerShares Dynamic Pharmaceuticals Fund (PJP) rounds out the field. Its tracking of a proprietary Intellidex Index has led to superior bull market performance. Here are the 4 choices since the March 9, 2009 lows:



Perhaps ironically, three of the Pharma ETF choices don't provide enough dividend yield, making the investor rely almost entirely on capital appreciation in bull market uptrends. The other, PPH, is so wrapped up in JNJ, one can't escape the company's decade-long underachievement.

It follows that there may be a sweeter way to get your cake (yield) and eat it too (capital appreciation). Consider a fifth option -- the iShares High Dividend Equity Fund (HDV). You get 27% exposure to "Big Pharma" as well as a 30-day, annualized SEC yield of 4%. And, HDV has done a fine job picking up "cap app" to boot.

Stock quotes in this article: XPH, IHE, PPH, PJP, HDV 
Disclosure Statement: ETF Expert is a website that makes the world of ETFs easier to understand. Gary Gordon, Pacific Park Financial and/or its clients may hold positions in ETFs, mutual funds and investment assets mentioned. The commentary does not constitute individualized investment advice. The opinions offered are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial or its subsidiaries for advertising at the ETF Expert website. ETF Expert content is created independently of any advertising relationships. You may review additional ETF Expert at the site.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 0.00 0.00%
S&P 500 1,878.61 +3.22 0.17%
NASDAQ 4,148.3380 +21.3710 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs